Correction: Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer
Enregistré dans:
Format: | article |
---|---|
Langue: | EN |
Publié: |
BMJ Publishing Group
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/839aaab9b4554eddb78c18a7f48b942e |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer
par: Leisha A Emens, et autres
Publié: (2021) -
Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer
par: Julia Foldi, et autres
Publié: (2021) -
Phase II trail of nab-paclitaxel in metastatic breast cancer patients with visceral metastases
par: Yizhao Xie, et autres
Publié: (2021) -
Targeting nucleotide metabolism enhances the efficacy of anthracyclines and anti-metabolites in triple-negative breast cancer
par: Craig Davison, et autres
Publié: (2021) -
A triple negative breast cancer: what it is not!
par: Katakkar SB
Publié: (2012)